{"entity":{"id":"nct05544227","kind":"trial","name":"Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer","aka":[],"tldr":"A phase 1 trial of SYNC-T Therapy SV-102 run by Williams Cancer Foundation, completed.","summary":"Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT05544227 by Williams Cancer Foundation, with 15 participants enrolled, started 2023-02-01. Conditions recorded: Metastatic Castration-resistant Prostate Cancer. Interventions recorded: SV-102.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05544227","url":"https://clinicaltrials.gov/study/NCT05544227"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["sv-102"],"companies":["syncromune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05544227","phase":"1","setting":"Immunotherapy Regimen Given After Targeted Local Cryolysis (TLC) for Patients With Advanced/Metastatic Castration-resistant Prostate Cancer (mCRPC) OR Those With Metastatic Prostate Cancer Who Refused Hormone Therapy and Chemotherapy.","sponsor":"Williams Cancer Foundation","enrolled":15,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05544227/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"sv-102","kind":"drug","name":"SYNC-T Therapy SV-102","route":"/drugs/sv-102/"}],"company":[{"id":"syncromune","kind":"company","name":"Syncromune","route":"/companies/syncromune/"}]}}